THRD Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -0.95%, SMA50 0.3%, SMA200 -24.43%). The stock’s 14-day RSI is 43.92 (neutral), while the ATR of 0.05 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -66.42% below its high and over 69.18% above its low.

Third Harmonic Bio, Inc. generated EPS of -$1.24 over the past year. Five-year average earnings growth is -34.7%. The latest quarter delivered EPS of -$0.26. The next quarter is forecast at $nan. Next year's EPS is expected at -$24.77. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $5.00. The high target offers -7.06% upside. The low target suggests -7.06% downside. The mean target is $5.00. This offers -7.06% upside. Third Harmonic Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended August 14, 2025, missed forecasts by 18.18%. The prior quarter beat by 34.62%. Over the last six quarters, Apple has recorded several small beats. These include -159.21% in May 16, 2024.

Third Harmonic Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $6.75. This means the shares are trading below this model’s fair value.

Third Harmonic Bio, Inc. has 45.13 million shares outstanding. The public float is 15.60 million shares, elevated short interest at 5.17% of float. This equals 1.42 million shares. The short ratio is 6.95 days. Institutional investors hold 88.15% of the float. Insiders own 9.11%. Atlas Venture Fund XI, L.P. holds 10.31 million shares, ORBIMED ADVISORS LLC has 5.78 million shares and Bonita David P has 5.78 million shares.

Our AI price prediction model suggests that Third Harmonic Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected rise of 34.01%, reaching $7.21 by November 10, 2025, with a range of $6.59 to $7.71. 1-Year Outlook: Projected loss of -32.71%, with price at $3.62 by August 12, 2026, within a range of $0.00 to $1.04.

The stock is currently mid-range between its 52-week high and low $3.18 and $16.02. With a market capitalization of about $242.79 million, Third Harmonic Bio, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.13). Key stats such as the average daily volume over the past year has been around 262.78 thousand shares, trading with heavier-than-usual volume. Headquartered in Cambridge, MA, Third Harmonic Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Natalie C. Holles, the company employs approximately 31 people and listed since September 14, 2022. Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases.

Third Harmonic Bio, Inc. (NASDAQ:THRD) shares are down -47.72% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Third Harmonic Bio, Inc. trading at a premium to the broader market with a P/E of -5.65. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $12.07, suggesting 124.35% upside.

Third Harmonic Bio, Inc. trades at a P/E ratio of -5.65, slightly below the S&P 500 average, with a price-to-sales ratio of 5058.07 and a price-to-book ratio of 0.89 suggesting the stock is closer to book value. The P/FCF stands at -7.38, also below market averages.